Angiogenesis in epithelial ovarian cancer

E S Bamberger, C W Perrett

Angiogenesis, the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelial ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.

Epithelial ovarian cancer (EOC) is the most common malignancy of the female genital tract in Western countries: 1–2% of all women develop EOC at some time during their lives. This disease begins in, and is usually limited to, the peritoneal cavity. Most women with EOC present with peritoneal spread, the principal cause of morbidity and mortality. EOC is associated with malignant ascites formation; in most cases, the first indication of EOC is swelling of the abdomen as a result of the accumulation of ascitic fluid. Owing to the paucity of symptoms and their insidious onset, most patients present with advanced disease, and five year survival rates are approximately 20%. At present, EOC has by far the worst prognosis of all gynaecological cancers and is responsible for half the deaths caused by female genital tract malignancy. The ovaries give rise to a wider variety of tumours than any other organ in the body. The main histological types of EOC are serous and mucinous tumours, with endometrioid and clear cell carcinomas being in the minority. Tumour type, stage, and grade have a bearing on the treatment and prognosis of EOC. Staging describes the extent of tumour spread and, of all the prognostic factors, probably has the greatest effect on treatment and prognosis. For EOC, the most commonly used system for staging is that of the International Federation of Gynaecology and Obstetrics (FIGO) within the majority of patients present with advanced disease, and five year survival rates are approximately 20%. At present, EOC has by far the worst prognosis of all gynaecological cancers and is responsible for half the deaths caused by female genital tract malignancy. The ovaries give rise to a wider variety of tumours than any other organ in the body. 1 The main histological types of EOC are serous and mucinous tumours, with endometrioid and clear cell carcinomas being in the minority. Tumour type, stage, and grade have a bearing on the treatment and prognosis of EOC. Staging describes the extent of tumour spread and, of all the prognostic factors, probably has the greatest effect on treatment and prognosis. For EOC, the most commonly used system for staging is that of the International Federation of Gynaecology and Obstetrics (FIGO). 2

The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.

Angiogenesis is the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelial ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.

At present, epithelial ovarian cancer has by far the worst prognosis of all gynaecological cancers and is responsible for half the deaths caused by female genital tract malignancy.

ANGIOGENIC FACTORS

Embryonic development, reproductive functions (including ovarian cycling), wound healing, rheumatoid arthritis, retinopathies, psoriasis, and tumorigenesis are all proliferative processes that are crucially dependent on the development of new blood vessels. Therefore, angiogenesis is a crucial factor in the progression of solid tumours and metastases, including EOC. The formation of the vascular stroma plays an important role in the pathophysiology of malignancy. In the absence of vascular support tumours may become necrotic, or even apoptotic. The onset of angiogenesis marks a phase of rapid proliferation, local invasion, and ultimately metastasis, although angiogenesis can also have a role to play in premalignant lesions (for example, those of the cervix and vulva). Vascularisation is a prerequisite for tumour cells to spread by shedding into the circulation; the newly formed, immature, and leaky capillaries aid the process of metastasis because their basement membranes are fenestrated, allowing greater accessibility for stray tumour cells.

ANGIOGENIC FACTORS

In recent years, much progress has been made in the identification of regulators of angiogenesis.

See end of article for authors' affiliations

Correspondence to:
Dr C W Perrett,
Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK; c.perrett@rfc.ucl.ac.uk

Accepted for publication 12 July 2002

Abbreviations: Ang, angiopoietin; AVD, average vessel density; bFGF, basic fibroblast growth factor; DFS, disease free survival; ELISA, enzyme linked immunosorbent assay; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynaecology and Obstetrics; HVD, high vessel density; IP mice, mice bearing intraperitoneal tumours; MVD, microvessel density; OHSS, ovarian hyperstimulation syndrome; PD-ECGF, platelet derived endothelial cell growth factor; PlGF, placental growth factor; α-SMA, α smooth muscle antigen; TGF, transforming growth factor; TP, thymidine phosphorylase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; VPF, vascular permeability factor; WVF, von Willebrand factor
Most notably, vascular endothelial growth factor (VEGF) is widely distributed and has been shown to play a coordinated role in endothelial cell proliferation and assembly of the vessel wall in a variety of normal and abnormal circumstances. There are now five members of the VEGF family, in addition to four members of the angiopeptin family and at least one member of the ephrin family of regulators;72 they must all work in a complementary and coordinated manner to form functional vessels.72 In addition, many other growth factors that are not vascular endothelial specific are also required for blood vessel formation, such as members of the platelet derived growth factor and transforming growth factor (TGF) families; these factors also have crucial roles in many other systems.72

**Angiogenic stimulators**

**VEGF**

Several naturally occurring growth factors and cytokines can induce and/or promote angiogenesis by stimulating endothelial cell growth and migration. One of the more potent endothelial mitogens is VEGF, also known as vascular permeability factor, VPF,73 because it was initially recognised for its ability to increase microvascular permeability.

VEGF/VPF (now termed VEGF-A) was first identified in 1993 by Senger and colleagues74 in the culture supernatant and ascites of rodent tumours. Later, VEGF was found in the malignant effusions of human ovarian, breast, and lung tumours.75 By virtue of its permeability inducing properties a central role for VEGF/VPF in tumour stroma generation has been suggested.72 75 In addition, VEGF can act as a specific mitogen for a variety of endothelial cells in vitro and as an angiogenic molecule in vivo.76 77 VEGF is a potent and very specific mitogen for vascular endothelial cells.78 79 It stimulates the full cascade of events required for angiogenesis both in vitro and in vivo,46 47 and greatly augments the permeability of the existing microvasculature.80 81 It is a potent multifunctional cytokine that exerts several potentially independent actions on the vascular endothelium,12 including endothelial mitogenesis, permeability, vascular tone, the production of vasoactive molecules, and the stimulation of monocyte chemotaxis.92 95 VEGF also functions as a potent prosurvival (antiapoptotic) factor for endothelial cells in newly formed vessels,90 92 and this may be one of its most important functions.

"Several studies have now shown that vascular endothelial growth factor is overexpressed in a variety of tumours including those of the breast, ovary, bladder, vulva, uterus, and cervix."97

The human VEGF gene has been mapped to chromosome 6p21.3.97 Biochemically, VEGF is a heparin binding glycoprotein that occurs in at least four molecular isoforms; these consist of 121, 165, 189, and 204/206 amino acids and are the result of alternative VEGF mRNA splicing.91-94 These isoforms have distinct functional properties in terms of heparin binding and diffusibility. VEGFα is the most common; it binds to heparin and can either be secreted or bind to the cell surface and extracellular matrix. VEGFβ is freely soluble and does not bind to heparin. VEGFγ is sequestered into the extracellular matrix and may be released by heparin or heparinase.

Several studies have now shown that VEGF is overexpressed in a variety of tumours including those of the breast, ovary, bladder, vulva, uterus, and cervix. VEGF values are often raised, and blocking its activity—for example, by specific neutralising antibodies to VEGF or to VEGF receptors (VEGFR) expressed by “activated” endothelial cells—can inhibit experimental tumour growth in vivo, but not in vitro.46 47 Thus, tumour cells can “feed” (induce) new blood vessels by producing VEGF which, in turn, can nourish the tumour cells, an insidious and self perpetuating paracrine loop. The possibility of therapeutic disruption of this loop has stimulated an intense search in the biotechnological and pharmaceutical industries, in addition to academic centres, for agents such as anti-VEGF antibodies,95-98 VEGF–toxin conjugates,99 aptamers,100 and small molecule VEGFR antagonists.101-103

The VEGF family

Recent observations have identified a group of several growth factors, the VEGF family, which interact with different receptors to induce endothelial mitogenesis. The most important member of the group is VEGF itself (VEGF-A). In addition to VEGF, the family currently includes; VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placent growth factors PlGF-1 and PlGF-2.26 27

Mice lacking VEGF-B are overtly normal and fertile, but their hearts are reduced in size, suggesting that VEGF-B may have a role in coronary vascularisation and growth.12 VEGF-C, based on its ability to bind the lymphatic specific receptor VEGFR-3 (see below), is important for lymphatic development, and transgenic overexpression of VEG-C leads to lymphatic hyperplasia.19 Little is known about the physiological role of VEG-D.26 Until recently, little was known about the normal function of PlGF, in part because mice genetically engineered to lack this growth factor were overtly normal.104 105 However, recent findings indicate that adult mice lacking PlGF exhibit deficiencies in certain models of adult vascular remodelling, raising the interesting possibility that the activity of PlGF may be limited to these settings.106

The various members of the VEGF family have overlapping abilities to interact with a set of cell surface receptors107 that trigger responses to these factors. These receptors are involved in initiating signal transduction cascades in response to the VEGF and PlGF proteins. They comprise a family of closely related receptor tyrosine kinases consisting of three members now termed VEGFR-1 (previously known as Flt-1), VEGFR-2 (previously known as KDR or Flk-1), and VEGFR-3 (previously known as Flt-3). In addition, there are several accessory receptors, such as the neuropilins,108 which seem to be involved primarily in modulating binding to the main receptors, although roles in signalling for these have not been ruled out. VEGFR-2 mediates the major growth and permeability actions of VEGF, whereas VEGFR-1 may have a negative role, either by acting as a decoy receptor or by suppressing signalling through VEGFR-2. Thus, gene knockout mice lacking VEGFR-2 fail to develop a vasculature and have very few endothelial cells,109 whereas mice lacking VEGFR-1 have an excess formation of endothelial cells, which abnormally coalesce into disorganised tubules.109 Mice genetically engineered to express only a truncated form of VEGFR-1, lacking its kinase domain, appear normal, consistent with the notion that the primary role of VEGFR-1 may be that of a decoy receptor.109 VEGFR-3 may be important for blood vessel development, but is unique among the VEGF receptors in that it is also expressed on lymphatic vessels, and may therefore have an important role in lymphangiogenesis.110

**Platelet derived endothelial cell growth factor/thymidine phosphorylase**

Another factor that has been shown to stimulate angiogenesis is platelet derived endothelial cell growth factor (PD-ECGF). Originally isolated from platelets, this 45 kDa protein promotes cell growth and chemotaxis in endothelial cells in vivo and angiogenesis in vitro.111 It has been found in various tissues such as the placenta, lung, endometrium, and ovary,112 in addition to certain cancer tissues.113 The enzyme thymidine phosphorylase (TP), which catalyses the reversible phosphorylation of thymidine to thymidine deoxyribose 1'-phosphate, has been shown to be homologous to PD-ECGF. The byproduct of this reaction, 2'-deoxy-D-ribose, has angiogenic activity.114

www.molpath.com
Angiopoietin 1 and angiopoietin 2
Angiopoietin 1 (Ang-1) and Ang-2 are growth factors that are ligands for the "tied", a family of receptor tyrosine kinases that are selectively expressed within the vascular endothelium, as are the VEGF receptors.9,92 Although both Ang-1 and Ang-2 bind tie-2, Ang-1 functions as an agonist whereas Ang-2 behaves as an antagonist at this receptor.44 Indeed, Ang-2 can cause the regression of newly formed vessels by stimulating endothelial cell apoptosis, unless VEGF is present, in which case the two collaborate to promote angiogenesis.98 The ligand for the structurally related receptor, tie-1, remains unknown.

The ephrin family
Numerous ephrin ligands (for example, ephrin A1, B1, and B2) bind to the Eph receptor tyrosine kinases; these comprise the largest known family of growth factor receptors and include EphA2, EphB2, EphB3, and EphB4.95 Recent knockout studies have suggested key roles for ephrin B2 and its EphB4 receptor during vascular development. Mouse embryos lacking ephrin B2 and EphB4 suffer fatal defects in early angiogenic remodelling that are somewhat reminiscent of those seen in mice lacking Ang-1 or tie-2. In adult settings of angiogenesis, as in tumours or in the female reproductive system, the endothelium of new vessels strongly re-expresses ephrin B2, suggesting that ephrin B2 may be important in these angiogenic settings.96 The various members of this family appear to regulate the interactions between arterial and venous endothelial cells, as reviewed by other authors.97,98

Tissue selective angiogenic stimulators
Recently, the identification of an angiogenic mitogen selective for one endothelial cell type (the endocrine gland endothelium) has been reported.99 The expression of this factor is largely restricted to steroidogenic glands, such as ovary, testis, adrenal cortex, and placenta. Although this protein shows no structural homology with the VEGF family, it displays several functional homologies, it has been designated endocrine gland derived VEGF.99

Angiogenic inhibitors
A large, growing, and structurally diverse family of endogenous protein inhibitors of angiogenesis has now been discovered, and the potential use of some of these molecules in the treatment of cancer has been evaluated.100 They include: thrombospondin 1,66,79 interferon α/β,101 the 16 kDa fragment of prolactin,102 angiostatin,103 endostatin,104 vascular endothelial cell growth inhibitor,105 vasostatin,106 Meth-1 and Meth-2,107 and cleavage products of platelet factor 4 and anti-thrombin III.106 Some of these are internal fragments of various proteins that normally lack antiangiogenic activity— for example, angiostatin is one or more fragment(s) of plasminogen108 and endostatin is a fragment of type XVIII collagen.109 Many of the precursor proteins are components of the extracellular matrix/basement membrane (for example, type XVIII collagen and thrombospondin) or members of the clotting fibrinolytic pathways (for example, plasminogen and anti-thrombin III).110

THE PROCESS OF ANGIOGENESIS
The process of angiogenesis in adult neovascularisation, including tumour formation, is currently understood as follows.26,84: angiogenesis is primarily mediated by VEGF, which drives endothelial cell proliferation, migration, and tube formation. Subsequently, Ang-1, in physiological situations, leads to vessel maturation and stabilisation. However, such stabilised vessels can be destabilised by Ang-2 and, in the presence of VEGF, a new round of angiogenesis can begin; in the absence of VEGF, vessel regression would ensue. The balance of at least two biological systems (VEGF–VEGFR and Ang–tie) along with the natural angiogenic inhibitors regulate the outcomes of vessel formation and vessel regression, and these complexities must be taken into account when designing and developing antiangiogenic agents.102

MICROVESSEL DENSITY
The degree of angiogenesis of a tumour, as assessed by microvessel density (MVD), has emerged as a powerful candidate for prognosis and as a predictive tool.103 In a multivariate analysis, MVD was found to be the most accurate prognostic indicator in breast carcinoma for disease free survival (DFS); better than size, grade, or oestrogen receptor status.104 In other studies, VEGF expression has been demonstrated in a variety of tumours and has been correlated with increased MVD and poor prognosis.105,106

"The degree of angiogenesis of a tumour, as assessed by microvessel density, has emerged as a powerful candidate for prognosis and as a predictive tool"107

Many studies have used measurements of MVD in regions of high vessel density (HVD), also termed vascular "hotspots", to assess the influence of tumour angiogenesis on prognosis. Early studies108–110 showed a prognostic value of MVD in breast cancer and cutaneous melanoma. Further studies have shown a link between MVD and prognosis in several solid tumours, such as those of the breast, lung, prostate, ovary, head and neck, cervix, oesophagus, colon, and non-small cell lung carcinomas.111–113 Kato et al confirmed the prognostic usefulness of tumour MVD in 377 Japanese patients with breast cancer, followed for a median of 10 years.114 A raised MVD was associated with both low relapse free and overall survival. Later Gehani et al specifically look at the association between tumour MVD and the subsequent development of bone metastasis in 200 patients with primary breast cancer followed for a minimum of five years.115 In multivariate analyses, only MVD and lymph node status remained significantly associated with bone metastasis.

Markers of blood vessels
A variety of endothelial cell markers have been used to highlight tumour blood vessels immunohistochemically. The most commonly used antibodies include those against factor VIII related antigen, CD31/PECAM-1, and CD34. Factor VIII related antigen forms part of the von Willebrand factor (vWF) complex and plays a role in the coagulation process.116 The platelet–endothelial cell adhesion molecule CD31/PECAM-1, is a transmembrane glycoprotein involved in cell adhesion,117 and CD34 is a surface glycoprotein of unknown function.118 The relative abilities of these antibodies to highlight the vasculature has been examined in several tumours,119–122 including EOC (SJ Amis et al, unpublished data, 2002).123,124 Detection of blood vessels in tissue sections has recently been modified so that it is now possible to discriminate between newly formed immature vessels and those that are more established and mature. It is based on the use of antibodies to α smooth muscle actin (α-SMA), which appear to stain mature vessels because they attract a "coat" of periendothelial support cells—that is, pericytes and smooth muscle (α-SMA positive) cells.125 In this regard, it is of interest to note that antiangiogenic therapeutic procedures, such as the blockade of tumour cell VEGF production, result not only in a drop in the vessel count, but also a change in the ratio of immature/mature vessels because of the relative vulnerability of the immature vessels to this, and most other, forms of antiangiogenic treatment.
Several studies have indicated that VEGF regulated angiogenesis is an important component of EOC growth. VEGF immunostaining has been demonstrated in the epithelial lining of benign ovarian neoplasms. MVD and the degree of expression of VEGF and its receptors in ovarian tumours are directly correlated with poor prognosis, suggesting that angiogenesis, possibly mediated at least in part by VEGF, influences disease progression. In a murine model of EOC, the drug FR118487, which inhibits angiogenesis by inhibiting basic fibroblast growth factor (bFGF) and VEGF activities, suppressed the in vivo growth and metastasis of a murine ovarian cancer cell line.

Olson et al were the first to demonstrate the constitutive gene expression of VEGF in normal and neoplastic human ovaries. They concluded that VEGF may be an important mediator of the ascites formation and tumour metastasis observed in neoplastic conditions of the ovary.

Using human ovarian tissue, Abu-Jawdeh and colleagues examined, by in situ hybridisation and immunohistochemical analysis, the expression of VEGF and its receptors in different ovarian tumour types (fig 1A). They reported that VEGF mRNA and protein were expressed by the neoplastic cells in all the malignant tumours evaluated, with most tumours showing strong expression of mRNA. Serous borderline tumours had variable VEGF mRNA expression. No definite expression of VEGF was seen in mucinous borderline tumours. No strong expression of VEGF mRNA was seen in normal ovarian cortex, including surface epithelium, and benign tumours. In addition, microvascular endothelial cells strongly expressed VEGF-R1 and VEGF-R2 mRNA and stained positively for VEGF protein in most of the malignant and borderline tumours examined. These findings suggested that VEGF plays an important role in the angiogenesis associated with ovarian neoplasms.

"The consistent message in these various studies is the potential importance of angiogenesis, as a prognostic tool, during transformation and acquisition of the invasive phenotype of advanced epithelial ovarian cancer"

Wong Te Fong and colleagues assessed VEGF in a selection of normal ovaries (n = 10), benign cystadenomas (n = 30), primary ovarian tumours including serous adenocarcinomas (n = 17), mucinous (n = 6), endometrioid (n = 7), and clear cell (n = 2). Immunohistochemically, 75% of the malignant tumours expressed VEGF compared with 13% in benign cystadenomas and 0% in borderline tumours and normal ovaries. There was a significant difference in VEGF expression between the histological subtypes: serous subtypes of benign and malignant tumours expressed higher amounts of VEGF proteins; serous adenocarcinomas had significantly higher VEGF expression compared with endometrioid carcinomas. An examination of the relation between VEGF expression and stage of the tumour in this study showed that late stage EOC had strong VEGF expression when compared with early stage EOC. In addition, VEGF-C was highly expressed throughout all the ovarian carcinoma subtypes (fig 1C), although it was not of prognostic value in this study. These results suggested that VEGF may be involved in the process of invasion and angiogenesis in serous tumours.
It also supports the notion that tumours initially do not require an extensive vasculature because they obtain their nutrients through diffusion. The high VEGF-C values seen in ovarian cancer imply that lymphangiogenesis is important in ovarian cancer.

Yamamoto and colleagues\(^{152}\) reported a higher proportion of VEGF positive malignant tumours and strong VEGF immunostaining in clear cell ovarian tumours, suggesting that the growth of peritoneal metastases is dependent on neovascularisation, and that VEGF may regulate angiogenesis in these deposits. Siddiqui and colleagues\(^{151}\) (and LF Wong Te Fong et al. Quantification of angiogenesis in primary and metastatic epithelial ovarian carcinomas. Presented at the Proceedings of the British Association of Cancer Research, July 2000, Glasgow) showed that VEGF expression within omental metastases (n = 61) is an independent prognostic indicator in patients with EOC, and that it also correlates with preoperative CA125 values and the extent of omental involvement.

In addition to the prognostic implications of this work, it also served to highlight the extent to which tumour masses can become ‘‘contaminated’’ by blood vessels. Many such vessels are very small and deformed, containing tortuositous, cork-screw structures, blind ends, and abnormal branching characteristics, thus making many of them almost impossible to detect in a normal haematoxylin and eosin stained tissue section. Consequently, the degree of tumour angiogenesis had been underestimated, and hence less appreciated, before the publication of this type of work.

The consistent message in these various studies is the potential importance of angiogenesis, as a prognostic tool, during transformation and acquisition of the invasive phenotype of advanced EOC. There is a relative increase in VEGF in late stage primary EOC and omental metastases compared with normal or benign tumours of the ovaries.

**VEGF in cyst fluid**

Yeo et al developed a sensitive and specific time resolved immunofluorometric assay for measuring VEGF in biological fluids.\(^{139}\) They reported findings with this assay in guinea pigs and patients with both malignant and non-malignant effusions. They also found that concentrations in human effusions provided a diagnostic test for malignancy, with a sensitivity of 66% and a specificity of 80%.

On the basis of the well established fact that ovarian cancers generate fluid filled cysts that contain secretory products of cancer cells, Abu-Jawdeh and colleagues\(^{128}\) hypothesised that cyst fluid could be used to measure VEGF production in ovarian lesions. They determined VEGF by immunofluorimetry in cyst fluid samples obtained from a small group of patients, including seven benign, two borderline, and two malignant tumours. Substantially higher VEGF concentrations were detected in the cyst fluid samples of the two malignant and two borderline tumours than in the seven benign serous cysts.

Using a highly sensitive enzyme linked immunosorbent assay (ELISA) Hazelton and colleagues\(^{154}\) measured VEGF in ovarian tumours obtained from a larger group of patients (13 ovarian cancer, 23 benign cysts and cystadenoma, five borderline tumours, and eight functional cysts). They also measured bFGF which, like VEGF, is thought to be a regulator of tumour angiogenesis.\(^{152} \)\(^{153} \) Their results showed that malignant ovarian cysts have greatly raised concentrations of VEGF. Benign ovarian cysts have either undetectable, or low amounts of VEGF, whereas borderline tumours secrete low to intermediate amounts of VEGF. In malignant cysts, bFGF values were either undetectable, or very low, and no significant differences were found in bFGF values among malignant, benign, borderline, and functional cysts.

These findings indicate that VEGF concentrations in ovarian cyst fluid may represent a useful biomarker of angiogenesis and tumour progression.

**VEGF in ascitic fluid**

EOC is characterised by widespread intraperitoneal carcinoma and the formation of large volumes of ascitic fluid.\(^{106}\) McClure and colleagues\(^{14} \) investigated the role of VEGF in ovarian hyperstimulation syndrome (OHSS), which is characterised by massive transudation of protein rich fluid from the vascular space into the peritoneal cavity and, to a lesser extent, pleural and pericardial cavities. They showed that VEGF is the major capillary permeability factor in OHSS ascites. Seventy per cent of the capillary permeability activity in OHSS ascites was neutralised by recombinant human VEGF antisera.

In the ascites fluid of human ovarian cancer cell line OVCAR-5 grown in mice, Folkman\(^{155}\) found VEGF concentrations of more than 6000 pg/ml and, in the same mice, serum concentrations in the range of only 30 pg/ml. When OVCAR-5 cells were grown in vitro, VEGF values in the conditioned medium reached greater than 1400 pg/ml, compared with less than 30 pg/ml for control medium without the tumour cells. In a patient with ovarian cancer, VEGF concentrations in the ascitic fluid were greater than 13 000 pg/ml.\(^{111} \)

Mesiano and colleagues\(^{146} \) directly assessed the role of VEGF in the growth and ascites formation associated with EOC. To that end, they used the human ovarian carcinoma cell line SKOV-3 to develop an in vivo model of ovarian cancer in immunodeficient mice that mimicked the intraperitoneal carcinoma and ascites production seen in women with this disease. They then used a function blocking monoclonal antibody (A4.6.1), which blocks the access of VEGF to both the VEGF-R1 and VEGF-R2 receptors, thereby specifically inhibiting tumour derived VEGF activity, and then they assessed the consequences on tumour growth, ascites formation, and disease progression. A4.6.1 significantly inhibited subcutaneous SKOV-3 tumour growth compared with controls. However, tumour growth resumed when A4.6.1 treatment was discontinued. In mice bearing intraperitoneal tumours (IP mice), ascites production and intraperitoneal carcinoma were detected three to seven weeks after SKOV-3 inoculation. A4.6.1 completely inhibited ascites production in IP mice, although it only partially inhibited intraperitoneal tumour growth. When A4.6.1 treatment was stopped, IP mice rapidly (within two weeks) developed ascites and became cachectic.

These data suggest that in ovarian cancer, tumour derived VEGF is obligatory for ascites formation. VEGF may play a major role in the progression of EOC by influencing both tumour growth through its promotion of tumour angiogenesis, and ascites production through its stimulation of vascular permeability. Neutralisation of VEGF activity may have clinical applications in inhibiting malignant ascites formation in EOC.

**VEGF in the serum of patients with EOC**

Overexpression of VEGF by ovarian cancer cells is a major mediator of angiogenesis in this tumour type and serum values may therefore serve as a prognostic tool. Kondo and colleagues\(^{146} \) directly assessed the role of VEGF in the serum of patients with EOC and found that concentrations of this growth factor in the sera of mice were significantly increased from undetectable by subcutaneous transplantation with a solid tumour. They also measured VEGF values in serum specimens obtained from patients with several types of cancer, including ovarian cancer (n = 9). Sera of individuals with no sign of disease (normal, n = 26) were also tested. VEGF values in the sera from the patients with EOC were significantly higher than those in the normal sera (around the detection limit of the assay).

Tempfer et al evaluated VEGF values in pretreatment serum samples of 60 patients with EOC (stages I–IV).\(^{111} \) They found that 25% of patients with EOC had raised serum concentrations of VEGF. The median VEGF serum concentration in patients with EOC was 466 pg/ml (range, 68–284 pg/ml). The 75% quartile was 826 pg/ml. These patients had significantly lower serum VEGF levels than the untreated controls, but there were no significant differences among patients with different stages of disease. However, the authors noted that these findings are preliminary and require further validation.
shorter overall and disease free survival. In a multivariate regression model considering tumour stage, lymph node involvement, and histological grade, serum VEGF proved to be an independent prognostic factor. This finding supports the proposal that serum concentrations of VEGF are not indicative of tumour bulk, but of strong tumour proliferation.

If these studies are confirmed in larger series, pretreatment serum VEGF values should be regarded as an additional factor for predicting outcome in patients with EOC. Owing to its independence from established prognostic factors, VEGF could be used for prognostic information in clinically relevant EOC subsets such as early stage or lymph node negative ovarian cancers.

VEGF and prognosis in EOC

There have been few studies to date examining the prognostic value of VEGF in EOC. In one, Paley et al assessed VEGF by in situ hybridisation in a cohort of borderline patients and those with stage I and stage II EOC. They found that VEGF expression was a significant and independent predictor for shorter relapse free survival and overall survival. Wong Te Fong et al reported that the five year survival rates of patients with EOC whose tumours were positive for VEGF were significantly worse than those of patients with VEGF negative tumours. Siddiqui and colleagues reported that VEGF expression (as assessed by immunohistochemistry) in omental specimens (from 66 patients with EOC) significantly correlated with survival, independent of the stage of the disease. The degree of VEGF expression was found to correlate with the extent of the omental disease, being highest in those patients where the omentum was “caked” with cancer.

These limited data show that VEGF may have an important role to play in the prognosis of EOC, as a negative predictor for patients with early and late stage presentations.

PD-ECGF/TP in ovarian tissue and omental metastases

Fox and colleagues raised a monoclonal antibody against recombinant PD-ECGF/TP and immunohistochemically examined its expression in a range of normal human tissues, including ovary, which stained positive. Reynolds and colleagues studied the expression of mRNA coding for four angiogenic factors in normal ovaries, benign, and malignant ovarian tumours: PD-ECGF/TP, VEGF, bFGF, and TGF-β. The sight of sampling (areas of high velocity blood flow) was directed by transvaginal colour Doppler imaging performed within 24 hours of surgery. All four factors were expressed to some extent, but no association with malignancy was found for the expression of bFGF or TGF-β. A weak association of mRNA expression was found for VEGF, and overexpression of PD-ECGF/TP mRNA in malignant tissue compared with benign tumours was highly significant; the lowest values were found in postmenopausal ovaries and six ovarian carcinoma cell lines. The tumour sample treated with chemotherapy before surgery had the lowest degree of expression of all the tumours, including both benign and malignant. PD-ECGF/TP was also overexpressed in the corpus luteum and the secretory phase, premenopausal ovary.

“Vascular endothelial growth factor may have an important role to play in the prognosis of epithelial ovarian cancer, as a negative predictor for patients with early and late stage presentations”

Wong Te Fong et al assessed the degree of neovascularisation in a selection of normal ovaries, benign cystadenomas, ovarian borderline, and malignant tumours. Their results showed that two of the 10 normal ovaries were positive for PD-ECGF/TP expression and, of the seven premenopausal specimens, both positive results occurred in premenopausal ovaries. These results support the notion that angiogenesis is a component of normal ovarian follicular and corpus luteum development. Furthermore, they showed that PD-ECGF/TP expression increased from normal, benign, borderline, and malignant ovarian tumours (although not significantly), and high PD-ECGF/TP expression correlated with poor survival.

Several other studies have found positive immunohistochemical expression of PD-ECGF/TP in EOCs (fig 1B). Similarly, Nakashiki and colleagues found that patients with advanced ovarian carcinomas showed an increase of PD-ECGF/TP expression in stromal cells. Fujikawa et al showed that PD-ECGF/TP mRNA was significantly higher in EOC specimens than in normal ovary specimens.

These various results indicate that, similar to VEGF, PD-ECGF/TP is of importance in the progression of early ovarian carcinomas and may also have some prognostic relevance.

MVD in ovarian tissue and omental metastases

In several studies, the activity of angiogenesis has been evaluated by the measurement of MVD. Amis et al studied microvascularisation in benign and malignant ovarian tumours (normal, 28; benign, 23; EOC, 36; borderline, two; unpublished data, 2002). Anti-vWF antibody was used as an endothelial marker. MVD was analysed in 97 paraffin wax embedded sections of ovarian samples of different histological subtypes, using a Quantimet 500+ image analyser. Despite following a widely described methodology, the MVD values were similar in malignant tumours and benign tumours. It seems that tumour heterogeneity with respect to MVD between different areas of the same section, or between corresponding areas in different sections and between different blocks from the same tumours was partly accountable. The similar MVDs in the benign and malignant tumours suggested that in ovarian tumours, angiogenesis is responsible for tumour growth rather than malignant transformation. These findings are consistent with the data of Orre et al, showing that the average microvessel counts in malignant serous and benign ovarian tumours, using anti-vWF, were similar and significantly less compared with other markers. This was thought to result from the reduced or even absent expression of vWF factor antigen in the smaller less mature microvessels of many tumours. Shamin and colleagues also found that MVD values in mucinous carcinomas were significantly higher than those of the serous adenocarcinomas, consistent with the results of other groups (fig 1D).

Nakashiki et al studied EOC and found that angiogenesis was equally stimulated regardless of stage. They suggested that angiogenesis might be induced differently, depending on the organ involved and the histological type of the tumour. The MVD in mucinous adenocarcinoma was the highest among the histological types, and that of clear cell carcinoma was significantly lower than that of the others. It is likely that angiogenesis is necessary for cancer cell growth and allows tumours to increase in volume, but that other mechanisms may play a crucial role in tumour progression in EOC.

Orre et al studied the association between raised MVD values in benign, mucinous, and serous tumours of the ovary. In mucinous tumours was studied with antibodies to CD31/PECAM-1, CD34, and vWF in relation to the different histological subtypes, stage, and patient outcome. CD31/PECAM-1 and CD34 immunostaining revealed increased MVD in both the HVD and average vessel density (AVD) regions of mucinous compared with serous and benign tumours. This staining also revealed increased MVD in early stage mucinous tumours compared with that seen in both early and late stage serous tumours. Reduced vWF compared with CD31/PECAM-1 and CD34 immunostaining was seen in both borderline and malignant mucinous and serous tumours, but not in benign tumours. Orre’s results contradict the putative association between increased MVD and poor
prognosis, and therefore imply that the degree and control of angiogenesis may differ between ovarian tumour types.

“Rather then spreading via the vasculature, ovarian tumours generally spread via peritoneal dissemination, and tumour angiogenesis is unlikely to play a role in this type of spread.”

Abulafia and colleagues assessed angiogenesis in the ovaries of two groups of women: (1) 49 consecutive women with primary stage I invasive disease and (2) 34 women with borderline tumours. Microvessels were highlighted by staining them for vWF. MVD was tested statistically, by various methods, for correlation with several related variables such as: patient age, race, parity, previous contraceptive use, histological type, tumour grade, tumour size, ascites, tumour exocertences, and disease free and overall survival. The MVD values of the ovarian specimens from group 1 were significantly higher than those of group 2. These results imply that the angiogenic switch occurs between benign ovarian epithelium and borderline disease. Therefore, angiogenesis becomes intensified with invasive capability. Among women with borderline disease, MVD did not differ significantly between serous and mucinous carcinomas. There was no correlation between MVD and age, tumour grade, tumour size, ascites, or tumour excrescences. Abulafia and colleagues suggested that tumour vascularity as assessed by immunohistochemical MVD might help gynaecologists and pathologists to differentiate between borderline and invasive tumours when the precise diagnosis is unclear.

In solid tumours, including EOC, there is a significant correlation between the incidence of metastasis and MVD in hotspot areas. These areas are thought to represent regions of ongoing tumour angiogenesis, in addition to the site of tumour cell entry into the circulation. However, rather than spreading via the vasculature, ovarian tumours generally spread via peritoneal dissemination, and tumour angiogenesis is unlikely to play a role in this type of spread. The growth of the primary ovarian tumour and its peritoneal metastases is dependent on continued blood vessel growth. Regions other than vascular hotspots may contribute to this growth.

MVD and the expression of angiogenesis in EOC

Nakanishi et al studied the association of VEGF and TGF-β with MVD and assessed the significance of their expression as prognostic factors in EOC. Sixty specimens of EOC were immunohistochemically stained for VEGF and TGF-β. Seventy-eight per cent of them expressed VEGF and 57% expressed TGF-β. No correlation between the intensity of VEGF or the intensity of TGF-β immunostaining and FIGO stage was found. However, the intensity of staining for VEGF in mucinous adenocarcinomas was significantly stronger than that seen in endometrioid adenocarcinomas and clear cell carcinomas. In addition, no correlation was found between VEGF or TGF-β immunoreactivity and primary tumour size, nodal status, and volume of ascites (or survival in the case of VEGF).

Nakanishi et al found that there was a tendency (although not significant) for MVD in VEGF rich tumours to be higher than in VEGF poor tumours. However, the MVD of VEGF rich/TGF-β positive tumours was significantly higher than that of VEGF poor/TGF-β negative tumours. In serous adenocarcinomas, the MVD in TGF-β positive tumours was significantly higher than that in TGF-β negative tumours. This study indicates that angiogenesis is an early event in EOC and is regulated differentially among the different histological types of tumours; VEGF and TGF-β cooperate to drive angiogenesis as measured by MVD.

Orre and colleagues were better equipped then before to test the hypotheses that the expression of VEGF and its receptors and EOC proliferation would be associated with increased tumour vascularisation, thereby establishing themselves to be of prognostic and/or predictive value. However, the results were not conclusive and VEGF immunostaining was not significantly stronger in HVD regions of malignant compared with borderline serous tumours. More importantly, VEGF immunostaining did not differ between tumour types; however, the proportion of VEGFR-1 and VEGFR-2 positive vessels was significantly lower in mucinous tumours, and no differences were seen between HVD and AVD regions. A VEGF mRNA signal was seen in two of seven borderline mucinous tumours, eight of 14 malignant serous tumours, and five of 13 benign tumours. A negative correlation between VEGFR-1 immunostaining and MVD was seen in benign and serous tumours. However, the EOC proliferation index (assessed with the marker PCNA) and VEGFR-1 positive samples were positively correlated in benign tumours.

Again, these results suggested that angiogenesis is an early event in EOC and is regulated differentially among the different histological subtypes of tumours; VEGF may play a role in the control of angiogenesis in serous and benign tumours, but it does not contribute to higher MVD values in mucinous tumours or influence the heterogeneity of MVD in ovarian tumours, as has been reported previously.

MVD and prognosis in EOC

Weidner and colleagues showed that MVD, assessed by immunohistochemical staining for endothelial cells, was an independent prognostic factor in breast carcinoma. MVD has since been reported as a possible prognostic indicator in numerous human solid tumours including breast, melanoma, prostate, non-small cell lung, gastric, and colorectal carcinoma.

van Diest et al were the first to assess the prognostic value of MVD in advanced EOC (table 1). All tumours studied (n = 49) were of the epithelial type, stages III or IV. The patients were treated by debulking surgery and cisplatin based chemotherapy. Staining of microvessels was performed on tumour material (routinely processed and embedded in paraffin wax), by immunohistochemistry with anti-vWF antibody. Microvessels were counted according to a standardised protocol. In contrast to breast cancer and melanoma, in this study MVD showed no association with other prognostic variables tested such as stage, bulky disease, grade, DNA ploidy, volume percentage epithelium, mitotic activity index, and mean nuclear area. However, in survival analysis (overall survival time between date of first operation and death of recurrent disease), a tendency for worse prognosis with higher MVD was found, although the results were not significant. In addition, a multivariate survival analysis found no additional prognostic value of MVD compared with the other prognostic factors tested. The conclusion from this study was that, although a tendency for worse survival with higher MVD had been found, vascularity did not seem to have a significant impact on survival of adequately debulked patients with advanced ovarian cancer treated with cisplatin.

In another study, Hollingsworth et al assessed vascularity in 43 advanced stage (III and IV) patients with EOC, using CD34. MVD and stage were associated with overall and disease free survival as assessed by Kaplan-Meier analysis. The plots showed that higher stage and higher MVD, at both low and high magnification, confer a worse prognosis for DFS. In addition, the plots suggested that higher stage and HVD at
Table 1  Summary of clinicopathological prognostic value of MVD in EOC

<table>
<thead>
<tr>
<th>Authors</th>
<th>No. of patients</th>
<th>Monoclonal antibodies to</th>
<th>EOC type</th>
<th>Correlations, results, and conclusions. Clinicopathological or prognostic value</th>
</tr>
</thead>
</table>
| van Deest et al (1995)       | 176            | vWF                            | FIGO III and IV                 | MVD shows no association with many other prognostic variables. In survival analysis: tendency for worse prognosis with higher MVD. MVD and stage are associated with DFS and overall survival in women at high risk of recurrence who may benefit from adjuvant chemotherapy. VEGF may be considered as a prognostic factor in advanced stage EOC. 
| Hollingsworth et al (1995)   | 165            | CD34                           | FIGO III and IV                 | MVD alone does not provide diagnostic information in these tumours. The VEGF group were associated with better survival. The study was not able to evaluate the relevance of VEGF immunohistochemistry. VEGF is often expressed heterogeneously in a slide. The expression of VEGF and TGF-β was associated with angiogenesis. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 
| Amis et al (unpublished data, 2002) | 138            | vWF                            | Different subtypes               | No significant prognostic value of VEGF was found for patients with EOC. No significant influence of expression on overall survival. The VEGF group were associated with better survival. TGF-β expression was associated with the promotion of angiogenesis and vascularisation. The expression of TGF-β and VEGF may be considered as a prognostic marker in EOC. | 
| Nakashiki et al (1997)       | 159            | vWF                            | Stage I–IV                       | No significant prognostic value of MVD was found for patients with EOC. MVD had no significant influence on overall survival. The expression of VEGF and TGF-β was associated with better survival. The VEGF group were associated with better survival. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 
| Orre et al (1998)            | 137            | CD31, CD34, vWF                  | Serous and mucinous tumours, borderline cystadenomas, and others | MVD may help to differentiate between low malignant potential and invasive tumours. MVD alone does not provide diagnostic information in these tumours. The expression of VEGF and TGF-β was associated with better survival. The VEGF group were associated with better survival. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 
| Alvarez et al (1999)         | 177            | CD31, vWF                         | Primary EOC: serous, endometrioid, mucinous, clear cell, and undifferentiated carcinomas Stage I–IV | MVD alone does not provide diagnostic information in these tumours. The expression of VEGF and TGF-β was associated with better survival. The VEGF group were associated with better survival. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 
| Abloula et al (2000)         | 166            | vWF                            | Primary stage I invasive. Stage I low malignant potential EOC | MVD alone does not provide diagnostic information in these tumours. The expression of VEGF and TGF-β was associated with better survival. The VEGF group were associated with better survival. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 
| Nakayama et al (2001)        | 172            | CD34                           | Stage I–IV serous, mucinous and others | MVD alone does not provide diagnostic information in these tumours. The expression of VEGF and TGF-β was associated with better survival. The VEGF group were associated with better survival. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 
| Oogawa et al (2002)          | 179            | CD34                           | Primary EOC. Stage I–IV          | MVD alone does not provide diagnostic information in these tumours. The expression of VEGF and TGF-β was associated with better survival. The VEGF group were associated with better survival. The expression of VEGF and TGF-β may be considered as a prognostic marker in EOC. | 

DFS, disease free survival; EOC, epithelial ovarian cancer; FIGO, Federation of Gynaecology and Obstetrics; MVD, microvessel density; OAS, overall survival; vWF, von Willebrand factor.
capillaries are counted to determine MVD. Angiogenesis assessed by these methods has been widely accepted as an independent prognostic factor in human breast carcinoma, but not in EOC. To find out how rich angiogenesis is in EOC, Nakayama et al performed a comparative analysis of MVD in ovarian and breast carcinoma, at the same time.\textsuperscript{13} This comparative study found that MVD was lower in EOC than in breast carcinoma. In addition, 19 of the 42 cases of EOC studied by Nakayama et al revealed no significant prognostic value of MVD in patients with EOC. In contrast, MVD may be a prognostic factor in patients with breast carcinoma.

Because angiogenesis, as assessed by MVD, did not correlate with the progression of EOC in the study of Nakayama et al (table 1),\textsuperscript{13} or in the previous studies, it seems that angiogenesis in the prevascular phase may be involved in the progression of ovarian neoplasms. However, angiogenesis in the vascular phase may not play an important role in EOC. The results of Nakayama et al revealed no significant prognostic value of MVD in patients with EOC. In contrast, MVD may be a prognostic factor in patients with breast carcinoma.

So far, there has been no report showing a significant prognostic value of MVD by multivariate analysis in EOC. This has been explained\textsuperscript{13} using the present data and previous findings as follows:

- Angiogenesis in EOC may not be as rich as that seen in other types of carcinoma, in which angiogenesis is an independent prognostic factor.
- The degree of variation of angiogenesis in each EOC may not be large enough to serve as a prognostic indicator.
- Angiogenesis in EOC seems to be dependent on histopathological subtype,\textsuperscript{13} as described above.

In summary, this recent comparative analysis of MVD in EOC with that in breast carcinoma\textsuperscript{13} indicates that angiogenesis may play an important role in the progression of breast neoplasms, but not in the progression of ovarian carcinomas.

CONCLUSIONS

The high mortality rate of ovarian cancer results predominantly from the occult progression of the tumour within the peritoneal cavity, with the initial diagnosis usually only being made at an advanced stage. Modifications in chemotherapy and/or surgery are unlikely in the near future to improve the poor prognosis associated with this disease. An improved understanding of the mechanisms regulating the growth of EOC cells may eventually lead to techniques that facilitate early diagnosis, establish the prognosis, or determine the response to treatment. Eventually, it may even be possible to design effective target treatments that will work by interfering with the biochemical processes that govern the growth of EOC cells.

ACKNOWLEDGEMENT

We thank Miss LF Long Te Fong and Mr F Moll for preparing the photomicrographs for this review.

Authors’ affiliations

E S Bamberger, Department of Biology, University of Haifa at Oranim, Tivon 36006, Israel
C W Perrett, Department of Obstetrics and Gynaecology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK

REFERENCES

Angiogenesis in epithelial ovarian cancer

357


Ferrara N, Seneca, Dvorak HF, 1992; and endothelial growth factor expression with tumour angiogenesis and the growth factor withdrawal.


Ferrara N, Seneca, Dvorak HF, 1992; and endothelial growth factor expression with tumour angiogenesis and the growth factor withdrawal.

Angiogenic switch during tumorigenesis. 


Gut cancers differentiate without CDX2

Cell differentiation in intestinal adenomas and carcinomas has been shown to be regulated independently of a transcription factor important in maintaining gut epithelium. A molecular study has shown a new in vitro model of premalignant adenoma cell lines to be suitable for understanding CDX expression and tumour development and has refuted a previous suggestion that transcription factor CDX2 plays a part in differentiation. CDX1 and CDX2 were expressed more in the adenoma cell lines compared to two carcinoma cell lines. When the cells were induced to stop growing by treatment with sodium butyrate, a natural product of the intestinal microflora, expression of CDX1 and CDX2 were unaffected in two selected adenoma cell lines but rose slightly in the carcinoma cell lines. Inducing differentiation by allowing the cell lines to grow to confluence, before assay for CDX1 and CDX2, gave similar results. However, the level of expression attained fell far short of that observed in the normal gut epithelium.

CDX1 and CDX2 were assayed by western blotting in six premalignant adenoma cell lines with high expression of these transcription factors and two carcinoma cell lines with lower CDX expression. CDX1 and CDX2 transcription factors, specified by Cdx genes, are reduced in the development of colorectal cancers. CDX2, at least, is important in transcribing genes for differentiation in intestinal epithelium. Existing evidence is based on in vitro studies with cell lines from colorectal cancers whereas this new evidence comes from adenoma cell lines, which are closer to “normal” colonic epithelium.


Orve M, Rogers PAW, VEGF, VEGFR1, VEGFR2, microvascular density and endothelial cell proliferation in tumours of the ovary. Int J Cancer 1999; 84:101–10.


